Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLCF. De Marinis, K. K. Laktionov, A. Poltoratskiy, I. Egorova,M. Hochmair,A. Passaro,M. R. Migliorino,G. Metro,M. Gottfried,D. Tsoi,G. Ostoros,S. Rizzato, G. Z. Mukhametshina,M. Schumacher,S. Novello, R. Dziadziuszko,W. Tang, L. Clementi,A. Cseh,D. KowalskiANNALS OF ONCOLOGY(2019)引用 0|浏览98暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要